These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3499967)

  • 21. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.
    Ricaurte GA; Irwin I; Forno LS; DeLanney LE; Langston E; Langston JW
    Brain Res; 1987 Feb; 403(1):43-51. PubMed ID: 3493827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
    Pérez-Otaño I; Oset C; Luquin MR; Herrero MT; Obeso JA; Del Río J
    Neurosci Lett; 1994 Jul; 175(1-2):121-5. PubMed ID: 7970192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
    Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
    Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The MPTP-treated mouse as a model of parkinsonism: how good is it?
    Heikkila RE; Sonsalla PK
    Neurochem Int; 1992 Mar; 20 Suppl():299S-303S. PubMed ID: 1365446
    [No Abstract]   [Full Text] [Related]  

  • 25. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
    Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
    J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
    Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
    Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
    Pifl C; Schingnitz G; Hornykiewicz O
    Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
    D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
    Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
    Rekha KR; Selvakumar GP; Santha K; Inmozhi Sivakamasundari R
    Biochem Biophys Res Commun; 2013 Nov; 440(4):664-70. PubMed ID: 24103762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets.
    Perry TL; Jones K; Hansen S; Wall RA
    Neurosci Lett; 1987 Mar; 75(1):65-70. PubMed ID: 3106859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment.
    Ricaurte GA; Langston JW; Delanney LE; Irwin I; Peroutka SJ; Forno LS
    Brain Res; 1986 Jun; 376(1):117-24. PubMed ID: 3487376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
    Date I; Asari S; Nishimoto A; Felten DL
    No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57 BL/6 mice.
    Sundström E; Luthman J; Goldstein M; Jonsson G
    Brain Res Bull; 1988 Aug; 21(2):257-63. PubMed ID: 2903784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Youngster SK; Sonsalla PK; Heikkila RE
    J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.
    Ishiwata K; Koyanagi Y; Abe K; Kawamura K; Taguchi K; Saitoh T; Toda J; Senda M; Sano T
    J Neurochem; 2001 Nov; 79(4):868-76. PubMed ID: 11723179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
    Heikkila RE; Sieber BA; Manzino L; Sonsalla PK
    Mol Chem Neuropathol; 1989 Jun; 10(3):171-83. PubMed ID: 2669769
    [No Abstract]   [Full Text] [Related]  

  • 38. Parkinsonism induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cats: behavioral, biochemical and pathological studies.
    Chen S; Zhou X; Xu D; Tang Q; Xu X
    Chin Med Sci J; 1993 Dec; 8(4):223-6. PubMed ID: 8032069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
    Ferger B; Teismann P; Earl CD; Kuschinsky K; Oertel WH
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):256-61. PubMed ID: 10543426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.